Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC).

Alberto F. Sobrero, Roger Sidhu, Timothy Price et al.|Journal of Clinical Oncology|2012

Cited by 5